AVTX vs. GLYC, VINC, SLGL, OCX, DRRX, KZR, EQ, EGRX, CASI, and OCUP
Should you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include GlycoMimetics (GLYC), Vincerx Pharma (VINC), Sol-Gel Technologies (SLGL), OncoCyte (OCX), DURECT (DRRX), Kezar Life Sciences (KZR), Equillium (EQ), Eagle Pharmaceuticals (EGRX), CASI Pharmaceuticals (CASI), and Ocuphire Pharma (OCUP). These companies are all part of the "medical" sector.
GlycoMimetics (NASDAQ:GLYC) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, community ranking and risk.
GlycoMimetics presently has a consensus target price of $10.00, suggesting a potential upside of 3,590.04%. Given Avalo Therapeutics' higher possible upside, equities research analysts plainly believe GlycoMimetics is more favorable than Avalo Therapeutics.
GlycoMimetics has a beta of 2.3, suggesting that its stock price is 130% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.
Avalo Therapeutics has higher revenue and earnings than GlycoMimetics.
GlycoMimetics has a net margin of 0.00% compared to GlycoMimetics' net margin of -1,639.50%. Avalo Therapeutics' return on equity of -88.40% beat GlycoMimetics' return on equity.
GlycoMimetics received 310 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 62.62% of users gave GlycoMimetics an outperform vote while only 31.25% of users gave Avalo Therapeutics an outperform vote.
In the previous week, GlycoMimetics had 3 more articles in the media than Avalo Therapeutics. MarketBeat recorded 5 mentions for GlycoMimetics and 2 mentions for Avalo Therapeutics. GlycoMimetics' average media sentiment score of 1.43 beat Avalo Therapeutics' score of 0.66 indicating that Avalo Therapeutics is being referred to more favorably in the news media.
75.2% of GlycoMimetics shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 8.7% of GlycoMimetics shares are owned by company insiders. Comparatively, 0.2% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
GlycoMimetics beats Avalo Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Avalo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avalo Therapeutics Competitors List
Related Companies and Tools
